Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 19/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | MME | P08473 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637640 | 0.95 | CTSA (0.81) | CTSACYP3A4MMEPTGS2 | |
| SCHEMBL15635745 | 0.94 | CTSA (0.79) | CTSACYP3A4MME | |
| SCHEMBL15636911 | 0.93 | CTSA (0.75) | CTSACYP3A4MMEPTGS2 | |
| SCHEMBL15636993 | 0.91 | CTSA (0.73) | CTSACYP3A4MMEPTGS2 | |
| SCHEMBL15637043 | 0.91 | CTSA (0.65) | CTSACYP3A4MME | |
| SCHEMBL15635752 | 0.91 | CTSA (0.75) | CTSACYP3A4MME | |
| SCHEMBL15636707 | 0.91 | CTSA (0.72) | CTSACYP3A4MMEPTGS2 | |
| SCHEMBL15635907 | 0.90 | CTSA (0.88) | CTSACYP3A4MME | |
| SCHEMBL14696191 | 0.89 | CTSA (0.62) | CTSACYP3A4MME | |
| SCHEMBL2321883 | 0.89 | CTSA (0.62) | CTSACYP3A4MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014053533-A1 | USE OF SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AS PHARMACEUTICALS FOR PREVENTION/TREATMENT OF ATRIAL FIBRILLATION | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-20100121004-A1 | PURIFICATION PROCESS FOR SEMICONDUCTING MONOMERS | XEROX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121004-A1 | PURIFICATION PROCESS FOR SEMICONDUCTING MONOMERS | TERT, ADH1A, PCNA | CTSA 3991/4885CYP3A4 748/4885MME 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.